Discontinuing directly acting antivirals during hepatitis C treatment: highlighting an infrequent but hostile event - 24/11/22
Highlights |
• | Treatment of chronic hepatitis C virus (HCV) with new direct-acting antiviral agents (DAAs) has been proven efficacious and safe in many clinical trials. |
• | Several factors influence patient compliance with DAAs, and cause treatment discontinuation, resulting in waste of money and effort that could exhaust the health care system. |
• | Treatment regimen, longer treatment duration, and unfavorable liver functions were associated with treatment discontinuation. |
Plan
Vol 46 - N° 10
Article 102042- décembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?